Therapeutic Proteins

News Therapeutic Proteins

• Double functionalisation of titanium-based nanoparticles for drug delivery

  Scientists in India report the functionalisation of TiO2 nanoparticles with two different biomolecules – tris-(nitrilo tris-acetic acid) and biotin. The biocompatible nanoparticles is non-cytotoxic and can deliver multiple biomolecules into the cell. In the future the nanoparticles could act as vehi more

• Monsanto and Complix sign collaboration to bring new technologies to agriculture

  Monsanto Company and Complix NV announced they have entered into a collaboration agreement to evaluate and develop Complix’s proprietary Alphabody® protein technology in the field of agriculture.Alphabodies are a unique class of protein therapeutics that are potentially active against a broad range more

• In line with its strategy, UCB expands its biotechnology base in Belgium
  

  In line with its strategy, and in preparation for the growing demand for biological medicines, UCB inaugurated its new pilot biotechnology plant at its Braine-L’Alleud site in Belgium. UCB’s new biologics pilot production facility was officially opened at a ceremony attended by Jean-Claude Marcourt, more

White papers Therapeutic Proteins

• Characterizing Biotherapeutics with HPLC
  

  As demonstrated here, there are a broad range of HPLC applications used in development, production, validation and release of protein therapeutics for human use. Some of the applications mentioned above are mandatory when submitting a new biopharmaceutical to approval at the regulatory agencies. The introduction of the first so-called biosimilars in Europe further increased the demand for highly efficient analysis methods. The continuous development of new stationary phases for the common modes of biochromatography, such as size exclusion, ion exchange and hydrophilic interaction chromatography support biochemists in increasing lab productivity and establishing high-throughput HPLC analysis not only for small molecules but also for large biopolymers more

Publications Therapeutic Proteins

• Polyvinylpyrrolidone microneedles enable delivery of intact proteins for diagnostic and therapeutic applications

  Publication date: Available online 3 May 2013Source:Acta Biomaterialia Author(s): Wenchao Sun , Zeynep Araci , Mohammed Inayathullah , Sathish Manickam , Xuexiang Zhang , Marc A. Bruce , M. Peter Marinkovich , Alfred T. Lane , Carlos Milla , Jayakumar Rajadas , Manish J. Butte We pres more

• Differential response in downstream processing of CHO cells grown under mild hypothermic conditions

  The manufacture of complex therapeutic proteins using mammalian cells is well established, with several strategies developed to improve productivity. The application of sustained mild hypothermic conditions during culture has been associated with increases in product titer and improved product qua more

• Allometry of factor VIII and informed scaling of next‐generation therapeutic proteins

  Abstract Allometric scaling has been applied to the pharmacokinetics (PK) of factor VIII (FVIII), but published relationships are based on relatively small subsets of available data. Numerous next‐generation forms of FVIII are being developed (e.g., Fc fusion, PEGylated, and liposomal formulatio more

Market studies Therapeutic Proteins

• iBio, Inc. (NYSE ) - Financial and Strategic SWOT Analysis Review

  iBio, Inc. (iBio, formerly iBioPharma, Inc.) is a biotechnology company, engaged in the development of vaccines and therapeutic proteins based on its plant-based iBioLaunch platform technology, which is used in the manufacture of biopharmaceuticals. Its products include influenza vaccines, biodefenc more

• Crucell Switzerland AG - Strategic SWOT Analysis Review

  Crucell Switzerland AG (Crucell) is a private biopharmaceutical company engaged in producing vaccines and antibodies. The company offers drugs to diseases related to various fields such as paediatric, travel and endemic and respiration. It manufactures vaccines: quinvaxem, hepavax-gene, MoRu-viraten more

• Biomm S.A. (BIOM4) - Financial and Strategic SWOT Analysis Review

  Biomm S.A. (Biomm) is a publicly held Brazil-based biotechnology company that is principally engaged in the development of technology for the production of human insulin and other recombinant proteins. Its technology is suitable for the production of therapeutic proteins such as calcitonin, interfer more

Websites Therapeutic Proteins